Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study
Publication date
2024-09
Authors
Uittenboogaard, Aniek
van de Velde, Mirjam
van de Heijden, Lisa
Mukuhi, Leah
de Vries, Niels
Langat, Sandra
Olbara, Gilbert
Huitema, Alwin D.R.
Vik, Terry
Kaspers, Gertjan J.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc
Abstract
The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine exposure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine exposure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.
Keywords
feasibility study, individualized dosing, pediatric oncology, pharmacokinetics, sub-Saharan Africa, vincristine, Pediatrics, Perinatology, and Child Health, Hematology, Oncology
Citation
Uittenboogaard, A, van de Velde, M, van de Heijden, L, Mukuhi, L, de Vries, N, Langat, S, Olbara, G, Huitema, A D R, Vik, T, Kaspers, G & Njuguna, F 2024, 'Vincristine exposure in Kenyan children with cancer : CHAPATI feasibility study', Pediatric Blood and Cancer, vol. 71, no. 9, e31160. https://doi.org/10.1002/pbc.31160